Amgen

Among the first biotech companies to turn genetic engineering into blockbuster medicine, Amgen made its name in the 1980s and 1990s with Epogen and Neupogen, drugs that boosted blood cells in patients on dialysis or chemotherapy. Today the catalog is broader: the bone-loss drug Prolia, the cholesterol shot Repatha, the anti-inflammatory Enbrel, and a pipeline the market is watching closely for an obesity treatment called MariTide. The 2023 purchase of Horizon Therapeutics added rare-disease drugs and a hefty debt load. Amgen sells high-priced biologics that face eventual competition from cheaper biosimilars, so the story is always about whether new launches can outrun older products going off patent. Based in Thousand Oaks, California, and founded in 1980, it remains one of the largest independent biotech firms.

On MyRWA, AMGN trades tokenized across 5 on-chain venues - see the listings below.